Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(33%)

Phase Distribution

Ph not_applicable
1
33%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution1 total trials
N/ANon-phased studies
1(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Terminated(1)
Other(2)

Detailed Status

unknown2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
N/A

Trials by Phase

N/A1 (100.0%)

Trials by Status

unknown267%
terminated133%

Recent Activity

0 active trials
Showing 3 of 3
unknownnot_applicable

(Phosphodiesterase 5 Inhibitors & α-blockers): Single Versus Combined Therapy in Benign Prostatic Hyperplasia

NCT05236634
unknown

Impact of Mirabegron on Erectile Function in BPH Patients

NCT04503850
terminated

Effect of Caldine® on Renal Function in Balanced Hypertension

NCT02240641

Clinical Trials (3)

Showing 3 of 3 trials
NCT05236634Not Applicable

(Phosphodiesterase 5 Inhibitors & α-blockers): Single Versus Combined Therapy in Benign Prostatic Hyperplasia

Unknown
NCT04503850

Impact of Mirabegron on Erectile Function in BPH Patients

Unknown
NCT02240641

Effect of Caldine® on Renal Function in Balanced Hypertension

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3